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Human tryptic C4d of the Chido and Rodgers variant was fragmented by cyanogen bromide and trypsin. 
The fragments were characterized by amino acid analysis and sequence determination. Polymorphism 
between the two genetic variants was detected in 5 positions. Four were closely located (residues 141, 142, 
145, 146), where Leu, Ser, Ile, His occurred in the Chido variant and Pro, Cys, Leu, Asp in the Rodgers 
variant, respectively. In position 94 Gly was found in Chido and Asp in Rodgers. Alignment of the 
fragments was performed and it is concluded that tryptic C4d of both variants contains 346 residues. 
Complement Human C4d Sequence Polymorphism Blood group 
1. INTRODUCTION part of the molecule in [9]. 
The complement factor C4 is a serum protein 
consisting of three disulfide linked polypeptide 
chains with M, 90000 (a-chain), 72000 (&chain) 
and 32000 (y-chain) [1,2]. As a constitutive part of 
the classical pathway of the complement system, 
C4, when activated, forms the classical C3-conver- 
tase in combination with C2 (review [3]). In serum 
C4 is degraded by factor I and C4-binding protein 
(C4bp) to C4c (Mr 140000) and C4d (MI 50000), of 
which the latter contains the labile binding site 
[4,5]. C4 is coded for by two separate loci, C4A 
and C4B, located within the major histocompatibi- 
lity complex (HLA in man) on chromosome 6 [6]. 
Based on electrophoretic mobility in agarose gels 
multiple alleles, including null alleles have been 
assigned to each locus. These differences appear to 
be localized to the m-chain, especially the C4d 
region [7]. 
The C4d fragment has been isolated from pool- 
ed serum and the amino acid sequence determined 
for 196 residues. While a homogenous sequence 
was observed for the N-terminal 90 amino acids 
[lo] heterogeneity was detected at 3 out of 106 
positions in a second region of C4d [I 11. Com- 
parison with the corresponding sequence predicted 
from the nucleotide sequence of a 304 base pair C4 
cDNA clone suggested heterogeneity even at a 
fourth position [ 121. 
Authors in [8] have shown that the blood groups 
Chido (i.e., C4B) and Rodgers (i.e., C4A) were 
associated with C4. The antigenic determinants for 
these blood groups have been located in the C4d 
We have isolated and separated C4d com- 
ponents of the Chido and Rodgers types from 
human C4 after digestion by trypsin [ 131. Tryptic 
C4d (try-C4d) was found to consist of a fragment 
with an M, of 28000-3OOOfl (designated A) carry- 
ing either the Chido or Rodgers determinants, and 
in addition a fragment with an M, of 7500 (desig- 
nated B) non-covalently associated with the larger 
polypeptide. This report describes detection of 
primary sequence differences at 5 positions be- 
tween the Chido and Rodgers try-C4d fragments. 
* Present address: Scripps Clinic and Research Founda- 
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2. MATERIALS AND METHODS 
2.1. Materials 
Sephadex G-75 (Pharmacia Fine Chemicals, 
Uppsala); TPCK-trypsin (Worthington Biochem. 
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[14C]methylamine and iodo-[3H]acetic amide (New 
England Nuclear, Boston, MA). 
(DITC) (LKB, Bromma, Sweden); controlled pore 
glass (CPG 10) (Sera Feinbiochemica, Heidelberg); 
[14C]methylamine and iodo-[3H]acetic amide (New 
England Nuclear, Boston, MA). 
2.2. Isolation of tryptic C4d 
Tryptic C4d of either the Chido or Rodgers 
variant and B-fragments from combined Chido 
and Rodgers variants was prepared from purified 
human C4 as in [ 131, with the glutamic acid residue 
and cysteine residue in the thiolester labelled with 
[14C]methylamine and the iodo-[3H]acetamide, 
respectively. The ‘larger fragment (A) was separat- 
ed from the 7500-Mr fragment (B) by gel filtration 
in 1 .O M acetic acid as in [ 131. 
2.3. Preparation of cyanogen bromide fragments 
A-fragments of either the Chido or Rodgers 
variant of tryC4d were digested with cyanogen 
bromide as in [ 141. The material was then chroma- 
tographed on Sephadex G-75 superfine (1 .O x 
135 cm) in 1.0 M acetic acid with a flow rate of 
3 ml/h. 
2.4. Preparation of tryptic fragments 
Peptide fragments were digested with TPCK 
trypsin (10 units trypsin/80 nmol peptide) at 37°C 
for 3 h in 0.1 M NH4HC03. The digestion was 
stopped by the addition of a double weight amount 
of SBTI over trypsin. Fragments were isolated by 
HPLC using a C 18 column (Waters radial com- 
pression separation system) in 0.16% trifluoro- 
acetic acid in Hz0 (v/v) with a linear gradient of 
acetonitrile containing 0.10% trifluoroacetic acid 
(v/v) from O-60%, The column was operated with 
a flow rate of 1.0 ml/min at room temperature, 
and the elution was monitored at 220 nm. 
2.5. Amino acid analysis and sequence deter- 
mination 
Amino acid analysis was performed as in [ 151. 
Manual Edman degradation was done by the direct 
phenylthiohydantoin method [la]. Automatic Ed- 
man degradation on solid phase was performed on 
an LKB 4020 solid phase peptide sequencer. CNBr 
peptides with a C-terminal homoserine were im- 
mobilized onto aminopropyl glass as in [ 171. Pep- 
tides without C-terminal homoserine were coupled 
to DITC-glass [ 181. Automatic Edman degrada- 
tion in liquid phase with polybrene [19] was per- 
formed in a Beckman 890C liquid phase sequencer 
equipped with a cold trap using a program de- 
scribed in [20]. The PTH amino acids were iden- 
tified by HPLC on a Nucleosil ODS column (4 x 
300 mm) in 6 mM sodium acetate buffer (pH 4.9), 
using a gradient of acetonitrile. 
3. RESULTS AND DISCUSSION 
Separation of CNBr peptides from either Chido 
or Rodgers variants of the A-fragment on G-75 
yielded 5 defined peaks (fig. 1). The elution profile 
was identical for material from both genetic 
variants. The material in each peak was subjected 
to amino acid analysis and to manual and auto- 
matic Edman degradation, and 6 different frag- 
ments were identified, designated CNl-6. CN3 
and CN4 eluted together, and this fraction con- 
tained the radioactive label. Manual Edman 
degradation of the CN3/CN4 fraction revealed a 
CpmK 10-S 
A2aor 
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015.. 
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Cl10 
0.05 
FRACTION NUMBER 
Fig. 1. Chromatography of cyanogen bromide fragments 
from Chido or Rodgers try-C4d on Sephadex G-75 
superfine in 1.0 M acetic acid (column 1 x 135 cm, flow 
rate 3.0 ml, fraction volume 1.0 ml). Approximately 
90 nmol of digest were dissolved in 50% (v/v) acetic acid 
and applied. Appropriate pools were taken. (-) 
Absorbance at 280 nm, (A---A, W-O) radioactivity. 
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double sequence. One of these (i.e., CN4) was 
identical to the N-terminal sequence of try-C4d 
reported by us in [ 121. The same sequence is also 
recognized in human C4d [lo], located 23 amino 
acids from its N-terminus (position 1 in fig.3), and 
the second sequence in the CN3/CN4 fraction 
(i.e., CN3) was found to be identical to the se- 
quence following the methionine in position 36 in 
fig.3. To obtain the C-terminal part of CN3 (which 
is not covered by the data in [lo]) the CN3/CN4 
pool was digested with trypsin and fragments 
isolated by HPLC on a Cl8 column. A tryptic 
nonapeptide (residues 64-72, fig.3) was found to 
overlap with the published sequence [lo]. The 
tripeptide Gly-Tyr-Hse was considered to con- 
stitute the C-terminal of CN3, and its position im- 
mediately C-terminal to the nonapeptide was 
determined by comparison with an overlapping 
peptide (residues 48-76, fig.3) (J. Gagnon and 
R.D. Campbell, personal communication). 
CNl was found to be contaminated with a pep- 
Table 1 
Amino acid composition of try-C4d CN2T5 from the 
Chido and Rodgers variants 
Amino acid Chido Rodgers 
Trp ND (3) ND (3) 
LYS 3.07 (3) 3.06 (3) 
His 0.97 (1) 0.20 (0) 
Arg 4.05 (4) 3.92 (4) 
Asp 4.19 (4) 5.45 (6) 
Thr 3.29 (3) 3.31 (3) 
Ser 10.69 (11) 9.66 (10) 
Hse 0.30 (1) 0.30 (1) 
G1l.l 12.37 (12) 12.16 (12) 
Pro 2.22 (2) 3.19 (3) 
GlY 5.29 (5) 4.53 (4) 
Ala 5.87 (6) 5.75 (6) 
CYS - (0) 1.20 (1) 
Val 3.94 (4) 3.89 (4) 
Ile 1.61 (2) 1.21 (1) 
Leu 9.00 (9) 9.00 (9) 
TYr 1.12 (1) 1.17 (1) 
Phe 2.99 (3) 3.07 (3) 
Values are given as mol of residue/m01 of peptide. ND, 
not determined. Thr and Ser were corrected using the 
recovery factors 0.96 and 0.89, respectively. Cys was 
determined as cysteic acid. Numbers in parentheses 
represent residues found in the sequence determination 
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tide which had an N-terminal sequence identical to 
CN3, probably representing incompletely digested 
material. CNlKN3 were co-sequenced for 15 
cycles whereafter the N-terminal sequence for CNl 
was deduced by subtracting the sequence of CN3. 
CN6 was found to consist of a dipeptide, Ala-Hse. 
CNS lacked homoserine, and was considered to 
represent he C-terminal of the A fragment. Since 
it also lacked lysine, the peptide was coupled to 
DITC-glass after conversion of the C-terminal 
arginine to ornithine [18] before 21 cycles of solid 
phase sequencing was performed. 
CN2 was of particular interest, since several 
amino acids in the composition differed between 
fragments derived from the Chido and Rodgers 
variants (see table 1). Solid phase sequencing of the 
35 N-terminal amino acids revealed only polymor- 
phism in residue 94, where the Chido variant con- 
tained glycine and the Rodgers variant an aspartic 
acid residue. The former statement was confirmed 
Fig.2. Separation of tryptic fragments from Chido CN2 
(A) and Rodgers CN2 (B) by HPLC in 0.16% (v/v) 
trifluoroacetic acid. The digestion mixture (220 pl, 
containing 40-80 nmol of peptide) was directly injected 
to the Cl8 column (8 x 100 mm). Flow rate 1.0 ml/min, 
fraction volume 0.4 ml. (-) Absorbance at 220 nm, 
(- - -) acetonitrile gradient. 
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by an extended automatic sequence determination 
of a Chido CN2 which covered 61 of the amino 
acids in the peptide. In order to complete the se- 
quence, CN2 from the Chido or Rodgers variants 
was digested with trypsin, and the fragments were 
separated by HPLC on a Cl8 column (fig.2). Of 
the 7 fragments obtained, designated TO-T6, T5 
from Chido eluted later than the corresponding 
Rodgers fragment. Automatic N-terminal se- 
quence analysis of the whole TS fragments re- 
vealed that the Chido and Rodgers variants dif- 
fered in positions 141 (Leu/Pro), 142 (Ser/Cys), 
145 (Ile/Leu) and 146 (His/Asp). No other dif- 
ferences were found between the tryptic fragments 
from the Chido and Rodgers variants of CN2 
except in T4, where the polymorphism in position 
94 (Gly/Asp) was confirmed. The localisation of 
serine in position 148 was deduced from the amino 
acid composition and confirmed by J. Gagnon and 
R.D. Campbell (personal communication). 
We were unable to detect any differences in the 
amino acid composition between Chido and 
Rodgers variants of the B-fragment, why pooled 
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material from both variants were processed 
together. The N-terminal sequence was determined 
for 20 residues and B was found to be a part of the 
C4d segment sequenced in [ 111, although their data 
do not cover the C-terminal end. The cyanogen 
bromide fragments from fragment B (designated 
CN7-9) were sequenced to the extent shown in 
fig.3. Trypsin digestion was performed on intact 
B, whereafter the digest was fractionated on Cl8 
(not shown). One of the isolated fragments (CN7) 
which overlapped with the C-terminal sequence 
described in [l 11 was completely sequenced (25 
residues), and considering the molecular mass of 
fragment B it was concluded to represent its C- 
terminal end. 
The alignment of the fragments is outlined in 
fig.3. CN3 is interposed between CN4 and CN2. 
The positions of CN2 and CNI are based on two 
overlaps (J. Gagnon and R.D. Campbell, personal 
communication), first the sequence Gly-Tyr-Met- 
Arg, which corresponds to the linkage between 
CN3 and CN2, and then Ser-Met-Gln-Gly-Gly-, 
which is found between CN2 and CNl. The pro- 
f To ‘to To 80 
VTASDPLDTLGSEGALSPGGVASLLRLPRGCGEETMIYLAPTLAASRYLDKTEQ~~T~PPETKDHAVOLIQKGYM~IQQ~- 
- CN4pt I 
100 120 140 ‘& 3> 160 
RKADGSYAAWLSR~SSTWL;AFVLKVLSLAQEQVG(;SPE/(LQETSNWLLSQQQADGSFQ~~~PV:HDRSMQGGLVGNDET;- 
ChCN2 \ ':U 
-RgCN2 \ -ChCNNTT- 
;64 
+RgCN2TI --RgCN2T5- 
720 240 260 1 280 
ALTA-----(X)6 -----ALTLTKAPAVDL~GVAHNNLM~MAQETGDNLYWGSVTGSQS~AVSPTPAPRNPSDPMPQAP~- 
f-i CNI CN5-I-CNg+--- 
iN7 7 
!OO 320 340 346 
LWIETTAYf~LNHBLLLHEGKAEMADQAAAWLTRQGSFQGG;RVIALDALSAYPIA;HTTEE~ 
I . I . 
\ -CN7TII- 
Fig.3. Amino acid sequence and alignment of cyanogen bromide (CN) and tryptic (T) fragments of try-C4d. The 
sequence of residues l-67 is taken from [lo] and of residues 220-325 from [ll]. The Chido sequence is displayed, and 
the variant amino acids found in Rodgers CN2 (residues 94, 141, 142, 145, 146) are shown above the Chido sequence. 
The polymorphism reported in [ll] at positions 228 and 231 are indicated. Arrows denote positive identification of 
PTH-amino acids from a particular fragment. The vertical arrow indicates the tryptic cleavage site between fragments 
A and B; 30-60 nmol of peptide were subjected to automatic sequence determination, and repetitive yields were 
96-98% and 90-92% for the liquid and solid phase sequencer, respectively. 
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posed length of CNl is based on the corresponding 
cDNA sequence (M. Carroll, personal communica- 
tion). The N-terminal sequence of the segment 
reported in [ 1 l] will then constitute the C-terminal 
part of CNl, followed by CN6 and then CN5, 
which locates the B fragment C-terminaily to the 
A-fragment. We have not found any evidence for 
the two polymorphic sites (positions 228 and 231) 
reported in the C-terminal part of CNI [ 111, but 
the contamination of CNl with undegraded 
CN3-CN2 limited the possibilities to discover such 
differences. Our sequence data of fragment B con- 
firmed the results in [l 11, except that only arginine 
(and no valine) was detected in position 32I, and 
histidine was found in position 292 instead of 
valine. In the latter case the cDNA was reported to 
code for histidine [12]. On the other hand, the 
cDNA codes for serine in position 307, where we 
and authors in [II] found alanine. 
Compared to tryptic C4d (346 residues} C4d 
generated with factor I and C4 binding protein [4] 
contains an additional 23 amino acids in the N- 
terminal end [lo] and an extra lo-15 amino acids 
in the C-terminus, the latter of which carries car- 
bohydrate (J. Gagnon and R.D. Campbell, per- 
sonal communication). Although the Chido and 
Rodgers variants of fragment A seem to have the 
same polypeptide chain length they migrate with 
different velocities on SDS-PAGE [ 131, sug- 
gesting that conformational differences exist bet- 
ween them, since carbohydrate has not been 
detected in try-C4d during this investigation. The 
same migration patterns have also been observed 
with the intact a-chains of the two variants [21]. 
Marked differences in hemolytic activity have been 
found for C4 from the two gene loci [6]. Even if 
it cannot be stated that the primary sequence dif- 
ferences reported here are responsible, it still re- 
mains a thrilling explanation. 
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